Compare NEU & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEU | BLCO |
|---|---|---|
| Founded | 1887 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.0B |
| IPO Year | 2004 | 2022 |
| Metric | NEU | BLCO |
|---|---|---|
| Price | $628.02 | $15.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $18.55 |
| AVG Volume (30 Days) | 132.8K | ★ 386.0K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 44.44 | N/A |
| Revenue | $2,725,169,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $8.63 |
| Revenue Next Year | N/A | $5.58 |
| P/E Ratio | $13.99 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $510.07 | $10.45 |
| 52 Week High | $875.97 | $18.92 |
| Indicator | NEU | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 38.57 |
| Support Level | $582.93 | $14.39 |
| Resistance Level | $646.28 | $17.66 |
| Average True Range (ATR) | 19.92 | 0.49 |
| MACD | 3.75 | -0.12 |
| Stochastic Oscillator | 73.71 | 19.62 |
NewMarket Corp is a holding company that, through its subsidiaries, manufactures and sells petroleum additives used in lubricating oils and fuels to enhance performance. The company operates through two segments: petroleum additives, mainly represented by Afton, where lubricant additives improve the efficiency and durability of base fluids and fuel additives help meet fuel specifications and improve fuel performance, and specialty materials, represented by AMPAC and Calca, including the antiknock compounds business of Ethyl, where primary raw materials include electricity, sodium chlorate, ammonia, chlorine, caustic, and hydrochloric acid, with graphite used in electrolytic cells. The company has operations in North America, Latin America, Asia Pacific, and EMEAI regions.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.